MUCINEX DM
LOE Approachingguaifenesin and dextromethorphan hydrobromide
NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Mucinex DM is a fixed-dose combination of guaifenesin (expectorant) and dextromethorphan hydrobromide (cough suppressant) formulated as an extended-release oral tablet. It is indicated for symptomatic relief of cough due to minor throat and bronchial irritation associated with the common cold or inhaled irritants. The expectorant thins mucus to facilitate clearance while the cough suppressant acts centrally to reduce cough reflex.
LOE Approaching
As an OTC product approaching loss of exclusivity with moderate competitive pressure, the brand team is likely focused on portfolio optimization and line extensions rather than expansion.
Mechanism of Action
Pharmacologic Class:
Expectorant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Mucinex DM offers exposure to OTC portfolio management, consumer marketing, and competitive positioning in a mature category. The approaching LOE stage suggests focus on cost management, market share defense, and transition planning—valuable experience in pharmaceutical product lifecycle management and portfolio strategy.
Brand ManagerCommercial Operations Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.